Peptide · Vial
Tesamorelin
From CA$10910mg20mg
A synthetic peptide that mimics a natural signal involved in the release of growth hormone.
Body composition research
Understand what was measured.
Explore products and studies related to adiposity, lean mass and other body-composition endpoints.
Start here
Begin with the question.
Body composition is broader than a number on a scale. Meaningful interpretation depends on which endpoint was measured, how it was measured, who was studied and whether the result belongs to an investigational or approved formulation.
- 01Was the endpoint body weight, fat mass, visceral adipose tissue or lean mass?
- 02Which population and formulation were actually studied?
- 03How long was follow-up, and what uncertainty remains?
Related products
Products in this collection.
Peptide · Vial
Retatrutide
From CA$14910mg20mg30mg40mg
An experimental compound designed to act on three metabolic hormone receptors at the same time.
Research compound · Vial
5-Amino-1MQ
From CA$9910mg50mg
A small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), studied in cell and animal models of metabolism.
Peptide · Vial
AOD9604
From CA$595mg10mg
A modified fragment of human growth hormone (amino acids 177–191) studied in research on fat metabolism.
Research compound · Vial
Lemon Bottle
Price coming soon10mg
A proprietary lipolysis formulation from cosmetic practice, reported to contain ingredients such as riboflavin, bromelain and lecithin.
Peptide · Vial
Tirzepatide
From CA$13910mg20mg30mg
A dual GIP and GLP-1 receptor agonist studied in metabolic research.
Peptide · Vial
5mg
A synthetic fragment from the C-terminal end of human growth hormone, studied in research on fat metabolism.
Peptide · Vial
Follistatin-344
$1691mg
A form of follistatin, a protein that binds myostatin and activin, studied in muscle-growth research.
Peptide · Vial
Cagrilintide
From CA$695mg10mg
A long-acting amylin analogue studied in appetite and weight-regulation research.
Blend · Vial
10mg
A blend of the amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide (5mg each), explored in metabolic research.
4 vialsSLU-PP-332
1 vialMOTS-cBundle · 5 vials
Non-GLP Metabolic Stack
5 vials
4 × SLU-PP-332 5mg and 1 × MOTS-c 10mg, bundled at 18% below the individual vial prices.
2 vials5-Amino-1MQ1 vialRetatrutideBundle · 3 vials
Lean Metabolic Stack
3 vials
2 × 5-Amino-1MQ 10mg and 1 × Retatrutide 10mg, bundled at 13% below the individual vial prices.
3 vialsTirzepatideBundle · 3 vials
Tirzepatide Research Stack
3 vials
3 × Tirzepatide 10mg, bundled at 13% below the individual vial prices.
3 vialsIpamorelin3 vialsTesamorelinBundle · 6 vials
GH & Metabolic Signalling Stack
6 vials
3 × Ipamorelin 5mg and 3 × Tesamorelin 10mg, bundled at 18% below the individual vial prices.
5 vialsRetatrutideBundle · 5 vials
Retatrutide Research Stack
5 vials
5 × Retatrutide 10mg, bundled at 20% below the individual vial prices.
Understand the context
Read the related research.
Clinical-trial review · 13 min
Retatrutide phase 2: how to read an early efficacy trial
What the randomized 48-week obesity study measured, what it observed and why the boundaries matter.
Read the guide
Clinical-trial review · 12 min
Tesamorelin trials: population, endpoint and follow-up
A plain-language reading of the phase 3 programme in adults living with HIV and excess abdominal fat.
Read the guide
Clinical-trial review · 12 min
Retatrutide in type 2 diabetes: comparator, endpoint and completion matter
How the 36-week phase 2 study separated glycaemic endpoints, active comparison and adverse-event reporting.
Read the guideCheck the exact batch